ScienceChina’s Akeso says cancer drug beat AstraZeneca’s Imfinzi in phase 3 trial

Chinese biopharmaceutical company Akeso said its immunotherapy drug ivonescimab, tested with chemotherapy, outperformed AstraZeneca’s Imfinzi in a head-to-head phase-three trial for biliary tract cancer. The company described the result as another breakthrough as China’s biopharma industry seeks a stronger global position.

Akesoivonescimabbiliary tract cancerclinical trial

SSouth China Morning Post★★★☆☆2026-08-27 02:07Original